HONG KONG, Jan. 26, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been accepted by the Center for Drug Evaluation (CDE)...
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso's Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA )
Also on site :
- Conquering Soccer and Arming Warlords
- Pope Leo XIV marks feast day as Vatican launches campaign to help erase its $57-68 million deficit
- Antigovernment protesters clash with riot police in Serbia